secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001193125-23-044902
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 3.03, 5.02, 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara stockholders approve merger with Enliven Therapeutics, authorize reverse stock split and share increase
--------------------------------------------------------------------------------

- Stockholders approved issuance of shares for merger with Enliven Therapeutics (21.4M for, 29K against).
- Authorized increase in common shares from 200M to 400M; approved reverse stock split at ratio of 1:3 to 1:7.
- Adopted Amended and Restated 2020 Equity Incentive Plan and increased ESPP shares to 1,628,535.
- Special meeting held Feb 22, 2023; all six proposals passed with requisite votes.
- Press release issued announcing voting results and reverse stock split details.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523044902/0001193125-23-044902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523044902/d466671d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-044902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer